LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Search

Dr Reddy's Laboratories Ltd-ADR

Fermé

SecteurSoins de santé

13.24 1.46

Résumé

Variation du prix de l'action

24h

Actuel

Min

13.02

Max

13.33

Chiffres clés

By Trading Economics

Revenu

-9.7B

2.2B

Ventes

-11B

76B

P/E

Moyenne du Secteur

24.556

49.888

Rendement du dividende

0.63

Marge bénéficiaire

2.928

Employés

27,527

EBITDA

-13B

6.1B

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.63%

2.38%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

68M

11B

Ouverture précédente

11.78

Clôture précédente

13.24

Sentiment de l'Actualité

By Acuity

50%

50%

155 / 344 Classement par Healthcare

Dr Reddy's Laboratories Ltd-ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 oct. 2025, 14:47 UTC

Principaux Mouvements du Marché

Esperion Therapeutics Shares Rise After Blocking Generic Version of Cholesterol Drug

12 mai 2026, 12:16 UTC

Résultats

Dr. Reddy's Co-Chairman: Branded Businesses, Currency Tailwinds Partially Mitigated Impact >500124.BY

12 mai 2026, 12:16 UTC

Résultats

Dr. Reddy's Co-Chairman: FY Performance Reflects Impact of Lower Lenalidomide Sales, Several One-Offs >500124.BY

12 mai 2026, 12:08 UTC

Résultats

Dr. Reddy's Laboratories Board Recommends Final Dividend of INR8/Shr >500124.BY

12 mai 2026, 12:06 UTC

Résultats

Dr. Reddy's Laboratories 4Q EPS INR2.64 >500124.BY

12 mai 2026, 12:02 UTC

Résultats

Dr. Reddy's Laboratories 4Q Net INR2.2B Vs. Net INR15.9B >500124.BY

12 mai 2026, 12:01 UTC

Résultats

Dr. Reddy's Laboratories 4Q Rev INR75.16B Vs. INR85.06B >500124.BY

23 juil. 2025, 17:49 UTC

Résultats

Dr. Reddy's Labs 1Q Global Generics Revenue $75.62B >RDY

23 juil. 2025, 17:48 UTC

Résultats

Dr. Reddy's Labs 1Q EPS $17.02 >RDY

23 juil. 2025, 17:48 UTC

Résultats

Dr Reddy's Labs 1Q Rev $85.45B >RDY

Comparaison

Variation de prix

Dr Reddy's Laboratories Ltd-ADR prévision

Note du Consensus

By TipRanks

Vente

1 ratings

0

Achat

0

Maintien

1

Vente

Sentiment

By Acuity

155 / 344Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Dr Reddy's Laboratories Ltd-ADR

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
help-icon Live chat